Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
China's 12th national Volume-Based Procurement round places RMB 60 billion across 65 drug varieties, accelerating generics and biosimilars substitution. Separately, Genialis launched BioBridge to help translate Chinese oncology trial results into Western development programs, as Chinese out-licensing hit $137.7 billion in 2025.
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Kelun-Biotech reported 2025 revenue of RMB2.06 billion with four products now marketed in China. The company's TROP2 ADC received multiple regulatory approvals for breast and lung cancer indications. A Phase 3 trial combining the ADC with pembrolizumab met its primary endpoint in first-line NSCLC treatment.
Recent studies reveal metformin's varied effects: it may extend lifespan in older women with diabetes by 30 percent, but failed to improve long COVID symptoms when given after infection developed.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07613307 |
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting |
RECRUITING | PHASE3 |
| NCT07603505 |
Effect of NAE on Polycystic Ovarian Syndrome (PCOS) |
COMPLETED | PHASE1 |
| NCT07576777 |
Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty |
NOT_YET_RECRUITING | NA |
| NCT07562724 |
Diet and WB-EMS Effects in Obesity |
NOT_YET_RECRUITING | NA |
| NCT07512609 |
Environment, Inflammation and Metabolic Diseases Study |
RECRUITING | |
| NCT07471607 |
Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes |
COMPLETED | NA |
| NCT07388537 |
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults |
NOT_YET_RECRUITING | |
| NCT07361887 |
Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. |
RECRUITING | NA |
| NCT07309913 |
China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) |
NOT_YET_RECRUITING | |
| NCT07206875 |
Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders |
NOT_YET_RECRUITING |
